Onsdag 9 Juli | 12:02:41 Europe / Stockholm

Kalender

Est. tid*
2025-08-29 07:00 Kvartalsrapport 2025-Q2
2025-04-25 - X-dag ordinarie utdelning TRMED 0.00 NOK
2025-04-24 - Årsstämma
2025-02-26 - Bokslutskommuniké 2024
2025-01-06 - Extra Bolagsstämma 2025
2024-08-30 - Kvartalsrapport 2024-Q2
2024-04-12 - X-dag ordinarie utdelning TRMED 0.00 NOK
2024-04-11 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-08-31 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning TRMED 0.00 NOK
2023-04-26 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-08-31 - Kvartalsrapport 2022-Q2
2022-04-29 - X-dag ordinarie utdelning TRMED 0.00 NOK
2022-04-28 - Årsstämma
2022-03-01 - Bokslutskommuniké 2021
2021-11-18 - 15-10 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-26 - Kvartalsrapport 2021-Q1
2021-04-28 - Årsstämma
2021-04-16 - X-dag ordinarie utdelning TRMED 0.00 NOK
2021-03-22 - Extra Bolagsstämma 2021
2021-02-18 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-10-21 - Extra Bolagsstämma 2020
2020-08-27 - Kvartalsrapport 2020-Q2
2020-06-11 - X-dag ordinarie utdelning TRMED 0.00 NOK
2020-06-10 - Årsstämma
2020-05-26 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-19 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-23 - Kvartalsrapport 2019-Q1
2019-04-26 - X-dag ordinarie utdelning TRMED 0.00 NOK
2019-04-25 - Årsstämma
2019-02-18 - Extra Bolagsstämma 2019
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-31 - X-dag ordinarie utdelning TRMED 0.00 NOK
2018-05-30 - Årsstämma
2018-05-30 - Kvartalsrapport 2018-Q1
2018-02-27 - Bokslutskommuniké 2017
2017-12-20 - Extra Bolagsstämma 2017
2017-11-22 - Kvartalsrapport 2017-Q3
2017-08-23 - Kvartalsrapport 2017-Q2
2017-05-26 - X-dag ordinarie utdelning TRMED 0.00 NOK
2017-05-24 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-02-28 - Bokslutskommuniké 2016
2016-11-23 - Kvartalsrapport 2016-Q3
2016-10-12 - Extra Bolagsstämma 2016
2016-08-24 - Kvartalsrapport 2016-Q2
2016-05-31 - Kapitalmarknadsdag 2016
2016-05-20 - X-dag ordinarie utdelning TRMED 0.00 NOK
2016-05-19 - Årsstämma
2016-05-19 - Kvartalsrapport 2016-Q1
2016-02-26 - Bokslutskommuniké 2015
2015-11-17 - Kapitalmarknadsdag 2015
2015-10-21 - Kvartalsrapport 2015-Q3
2015-08-26 - Kvartalsrapport 2015-Q2
2015-05-27 - Kvartalsrapport 2015-Q1
2015-03-09 - Årsstämma
2014-11-12 - Extra Bolagsstämma 2014

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriLäkemedel & Handel
Thor Medical är ett läkemedelsbolag. Bolaget är specialiserat inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo, Norge.
2020-02-26 16:57:52

Nordic Nanovector ASA (OSE: NANO) announces that Dr Lars Nieba has been appointed interim Chief Executive Officer with immediate effect. Dr Nieba, who is currently the Company's Chief Technology Officer, replaces Eduardo Bravo who as of today has left Nordic Nanovector to pursue other career opportunities.

Dr Nieba joined Nordic Nanovector on 1 December 2019 from Bayer AG where he served in various operational and strategic roles, Dr Nieba was most recently responsible for driving Bayer's Chemistry, Manufacturing and Controls (CMC) strategy for biologicals. He joined Bayer in 2016 following 13 years at F. Hoffmann-La Roche Ltd., where he held various leadership roles in clinical, operations, supply planning, biologics technology and technical business development. Prior Dr Nieba worked for Cytos Biotechnology where he served as Head of Therapeutic Vaccine Research.

Dr Nieba gained a PhD from the Max-Planck-Institute for Biochemistry, München and Institute for Biochemistry at the University of Zürich, and an Executive MBA from the University of St. Gallen, Switzerland.

Jan H. Egberts, MD, Chairman of Nordic Nanovector, commented: "The Board is very pleased to appoint Lars Nieba as Nordic Nanovector's interim CEO. We believe that his significant operational, development and product supply expertise will be crucial as we work towards completing the PARADIGME study and prepare for the planned filing for Betalutin® with the FDA. On behalf of the Board I would like to thank Eduardo for his contribution as CEO."

For further information, please contact:

IR enquiries

Jan H. Egberts, Chairman of Nordic Nanovector

Tel: +31 614672518
Email: janegberts@aol.com

 

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

Forward-looking statements

This press release contains certain forward-looking statements.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking